Melanoma Research Today is a free monthly online journal that collates and summarizes the latest research about Melanoma, including details on identification, causes, prevention, treatment.

Volume 3 (2006), Issue 3 (March)

1. Risk of second primary malignancies in women with papillary thyroid cancer.
   Am J Epidemiol, 163(6): 521-7. [Abstract] [Full-text]
2. Mast cells and angiogenesis in canine melanomas: malignancy and clinicopathological factors.
   Vet Dermatol, 17(2): 141-6. [Abstract] [Full-text]
3. Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients.
   Int J Cancer, 118(10): 2617-27. [Abstract] [Full-text]
4. Amplification of CDK4 and MDM2 in malignant melanoma.
   Genes Chromosomes Cancer, 45(5): 447-54. [Abstract] [Full-text]
5. Comparison of risk patterns in carcinoma and melanoma of the skin in men: a multi-centre case-case-control study.
   Br J Cancer, 94(5): 743-51. [Abstract] [Full-text]
6. An unusual case of tumor-to-cavernoma metastasis. A case report and literature review.
   Surg Neurol, 65(4): 402-8, discussion 409. [Abstract] [Full-text]
7. RhoC promotes human melanoma invasion in a PI3K/Akt-dependent pathway.
   J Invest Dermatol, 126(4): 862-8. [Abstract] [Full-text]
8. Circulating tyrosinase and MART-1 mRNA does not independently predict relapse or survival in patients with AJCC stage I-II melanoma.
   J Invest Dermatol, 126(4): 849-54. [Abstract] [Full-text]
9. Identification of identical TCRs in primary melanoma lesions and tumor free corresponding sentinel lymph nodes.
   Cancer Immunol Immunother, 55(5): 495-502. [Abstract] [Full-text]
10. Iris ring melanoma: fine needle biopsy.
    Br J Ophthalmol, 90(4): 420-2. [Abstract] [Full-text]
11. Piper longum inhibits VEGF and proinflammatory cytokines and tumor-induced angiogenesis in C57BL/6 mice.
    Int Immunopharmacol, 6(5): 733-41. [Abstract] [Full-text]
12. Slip! Slap! Slop! Cutaneous malignant melanoma incidence and social status in New Zealand, 1995-2000.
    Health Place, 12(3): 239-52. [Abstract] [Full-text]
13. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
    Eur J Surg Oncol, 32(3): 318-24. [Abstract] [Full-text]
14. Hepatic resection for malignant melanoma.
    Eur J Surg Oncol, 32(3): 315-7. [Abstract] [Full-text]
15. HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma.
    Int J Cancer, 118(11): 2657-64. [Abstract] [Full-text]
16. Contact of high-invasive, but not low-invasive, melanoma cells to native collagen I induces the release of mature cathepsin B.
    Int J Cancer, 118(11): 2735-43. [Abstract] [Full-text]
17. Small ciliary body tumors: ultrasound biomicroscopic assessment and follow-up of 42 patients.
    Am J Ophthalmol, 141(4): 622-8. [Abstract] [Full-text]
18. Nanosecond pulsed electric fields cause melanomas to self-destruct.
    Biochem Biophys Res Commun, 343(2): 351-60. [Abstract] [Full-text]
19. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma.
    Cancer, 106(7): 1431-42. [Abstract] [Full-text]
20. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma.
    Cancer Immunol Immunother, 55(7): 761-74. [Abstract] [Full-text]
21. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate.
    Cancer Immunol Immunother, 55(7): 819-29. [Abstract] [Full-text]
22. Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3.
    Cancer Immunol Immunother, 55(7): 785-96. [Abstract] [Full-text]
23. Therapeutic efficacy of tumor-targeted IL2 in LTalpha(-/-) mice depends on conditioned T cells.
    Cancer Immunol Immunother, 55(7): 861-6. [Abstract] [Full-text]

© 2004-2008 Melanoma Research Today. All Rights Reserved.